Bristol Takes Option To Buy Danish Biotech, Increases Efforts In Fibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol can buy out Galecto any time up to 60 days after the completion of a Phase Ib study of an inhalable drug candidate for idiopathic pulmonary fibrosis. The deal follows just weeks after FDA approved the first two drug therapies for IPF.